Case Report: Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse.
Affiliation
Department of Endocrinology, Beaumont Hospital, Dublin, Ireland.Issue Date
2010-12-24
Metadata
Show full item recordCitation
Case Report: Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse. 2010:notDiabet MedJournal
Diabetic medicine : a journal of the British Diabetic AssociationDOI
10.1111/j.1464-5491.2010.03226.xPubMed ID
21204965Abstract
Background Recent large-scale randomized trials of intensive therapy in Type 2 diabetes have reported increased cardiovascular morbidity and mortality in patient populations who experience a high frequency of hypoglycaemic events. However, there are few descriptions of hypoglycaemia leading directly to a myocardial infarct in the medical literature to date. Case report In this article we describe the case of a 76-year-old woman without diabetes who presented with symptoms, left bundle branch block and raised troponin, indicative of a myocardial infarction. She was also noted to be hypoglycaemic with a plasma glucose level of 2.5 mmol/l. It was subsequently discovered that she had mistakenly been dispensed glibenclamide, a long-acting sulphonylurea, in the preceding weeks. Her cardiac symptoms resolved completely upon treatment of her hypoglycaemia and she had no significant coronary artery disease on angiography. Conclusion This is the first case of sulphonylurea-induced myocardial infarct in a patient without diabetes and illustrates the adverse effects of acute hypoglycaemia upon the cardiovascular system.Item Type
Article In PressISSN
1464-5491ae974a485f413a2113503eed53cd6c53
10.1111/j.1464-5491.2010.03226.x
Scopus Count
Collections
Related articles
- Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
- Authors: Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D
- Issue date: 2008 Jun
- Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
- Authors: Du L, Chen Y, Shen J, Peng Y, Sun X
- Issue date: 2014 Jul
- Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
- Authors: Juurlink DN, Gomes T, Shah BR, Mamdani MM
- Issue date: 2012 Dec
- Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
- Authors: Sillars B, Davis WA, Hirsch IB, Davis TM
- Issue date: 2010 Sep
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
- Authors: Monami M, Genovese S, Mannucci E
- Issue date: 2013 Oct